
NeurologyLive® Friday 5 — November 20, 2026
Key Takeaways
- Subtle early-onset Alzheimer disease presentations can be underrecognized, and blood biomarkers are increasingly positioned to complement clinical assessment and accelerate referral and diagnostic workups.
- The 2027 MDA meeting agenda signals neuromuscular drug development trends, with care delivery and translational science priorities shaping near-term research and clinical practice.
Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending November 20, 2026.
Welcome to NeurologyLive®'s Friday 5! Every week, the staff compiles 5 highlights of NeurologyLive's widespread coverage in neurology, ranging from newsworthy study findings and FDA action to expert interviews and peer-to-peer panel discussions.
Don’t have time to read or watch a full video interview?
Click the read more or watch now buttons for more details and information about each highlight.
1: Recognizing Early-Onset Alzheimer Disease and the Role of Blood Biomarkers
In a recent Q&A interview, Allison B. Reiss, MD, associate professor of medicine at NYU Grossman Long Island School of Medicine, discussed the often-overlooked early signs of early-onset Alzheimer disease.
2: Navigating a New Era of Neuromuscular Drug Development and Care at MDA 2027
In a recent Q&A interview, Angela Lek, PhD, chief research officer at the Muscular Dystrophy Association, discussed how the 2027 MDA Clinical and Scientific Conference agenda reflects key themes in neuromuscular medicine.
3: Benjamin Greenberg, MD, MHS, on Highlights From the 2026 Rare Neuroimmune Disorders Symposium
In a recent Q&A interview, Benjamin Greenberg, MD, MHS, professor of neurology at UT Southwestern Medical Center, discussed emerging trials, proposed changes to myelitis diagnostic criteria and nomenclature, and the unmet needs raised by patients at this year’s symposium.
4: NeuroVoices: Brian Lin, PhD, on the FDA Approval of Gefurulimab for Generalized Myasthenia Gravis
In a recent Q&A interview, Brian Lin, PhD, senior director of research at the Muscular Dystrophy Association, discussed what the newly approved once-weekly C5 inhibitor adds to generalized myasthenia gravis care.
5: Myelin Repair Research in MS: Lessons From Clinical Trials and the Road Ahead
In a recent Q&A interview, Nick Cunniffe, MD, PhD, assistant professor and consultant neurologist at the University of Cambridge, discusses lessons from a decade of proof-of-concept remyelination trials in MS.
Which conversation stood out most to you in this week’s NeurologyLive Friday Five?
Related to this article








